EUVIMEDEUVIMED entdecken
Crossref

Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders

Yoshiki Nagai iD, Issei Takahashi iD, Naoto Yokogawa iD, Kota Shimada iD

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Yoshiki Nagai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Rituximab, Arthritis, Rheumatoid, Antirheumatic Agents, Lymphoproliferative Disorders. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The present study aimed to evaluate the efficacy, safety, and retention rate of rituximab (RTX) in Japanese rheumatoid arthritis (RA) patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD).

Methods

Between January 1, 2014, and July 31, 2024, 3 392 RA patients were registered in our institutional database, and 74 of these had OIIA-LPD. Amongst patients who achieved remission after the onset of OIIA-LPD, those who subsequently received RTX were retrospectively identified. Clinical data, including the Disease Activity Score for 28 joints-C reactive protein (DAS28-CRP) value, Clinical Disease Activity Index (CDAI) score, adverse events, and RTX retention rate, were analyzed.

Results

Fourteen patients received RTX for RA after OIIA-LPD remission. The mean DAS28-CRP value at baseline and at month 6, 12, 24, and 36 was 3.91 ± 1.40, 3.03 ± 3.20, 2.45 ± 1.09, 2.22 ± 0.62, and 1.93 ± 0.78, respectively. The respective CDAI score was 15.2 ± 7.74, 4.91 ± 3.80, 6.19 ± 4.46, 5.08 ± 3.03, and 4.18 ± 3.28. Four infections were observed. The RTX retention rate at month 12, 24, and 36 was 85.1%, 76.6%, and 76.6%, respectively.

Conclusions

Even in real-world clinical practice, RTX demonstrated long-term efficacy in reducing disease activity in Japanese RA patients with a history of OIIA-LPD. RTX appears to be a viable treatment option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabArthritis, RheumatoidAntirheumatic AgentsLymphoproliferative DisordersHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeJapanIatrogenic DiseaseAdultEast Asian People

Stichwörter der Autor:innen

Other iatrogenic immunodeficiency-associated lymphoproliferative diseaserheumatoid arthritisrituximab

Substanzen

RituximabAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

ORCID-Profile: Yoshiki Nagai, Issei Takahashi, Naoto Yokogawa, Kota Shimada

Zitieren

APA

Nagai, Y., Takahashi, I., Yokogawa, N., & Shimada, K. (2025). Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders. Modern Rheumatology. https://doi.org/10.1093/mr/roaf114

Vancouver

Nagai Y, Takahashi I, Yokogawa N, Shimada K. Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders. Modern Rheumatology. 2025. doi:10.1093/mr/roaf114

BibTeX
@article{Nagai2025,
  author = {Nagai, Yoshiki and Takahashi, Issei and Yokogawa, Naoto and Shimada, Kota},
  title = {Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf114}
}
Kostenlos starten →